EMPAVELI Strengthens Its Position in Rare Disease Market EMPAVELI, a C3 inhibitor for paroxysmal nocturnal hemoglobinuria (PNH), achieved $98.1 million in 2024 revenue. With FDA Priority Review and Fast Track Designation, it is being tested for additional conditions like C3G and HSCT-TMA, potentially expanding its market impact beyond PNH.1